4.5 Article

Easy to Swallow Instant Jelly Formulations for Sustained Release Gliclazide Delivery

Journal

JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 109, Issue 8, Pages 2474-2484

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2020.04.018

Keywords

Dysphagia; Paediatric; Geriatric; Controlled release; Swallowing; Microparticles

Funding

  1. Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, United Kingdom
  2. Hertfordshire Knowledge Exchange Partnership (HKEP)
  3. European Regional Development Fund (ERDF), Local Enterprise Partnership (LEP), University of Hertfordshire, United Kingdom
  4. Fluid Pharma Ltd.

Ask authors/readers for more resources

It is a challenge to safely administer sustained release medicines to patients with dysphagia. Sustained release tablets must not be crushed and multiparticulates with large particle sizes cause gritiness reducing patient acceptability. The aim of this study was to develop instant jellies as delivery vehicles incorporating sustained release microparticles for patients with dysphagia. Dry powder mixtures containing gelling agents such as sodium alginate and calcium ions were hydrated in 20 mL of water and formed a jelly texture within 10 min. The instant jellies demonstrated comparable properites to commercial read-to-eat jellies in appearance, rheological/textural properties and in vitro swallowing performance in an artificial throat model. Gliclazide sustained release microparticles were produced by fluidized bed coating using Eudragit (R) NM 30 D and achieved 99% production yield and final coated particle size (D-50) of 198 +/- 4.3 mm. Sustained gliclazide release was achieved over 15 h and the incorporation of the particles into the jellies significantly decreased the drug release rate. This novel drug delivery system offers a patient-centric solution to the long-standing challenge of administering sustained release medicines to patients with dysphagia and can potentially be used for paediatric patients. (c) 2020 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association (R). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available